Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus moderate-dose aspirin plus IVIG for prevention of coronary artery abnormalities in Kawasaki disease
ChiCTR2300072686Phase 4Recruiting
- Sponsor
- Guangzhou Women and Children's Medical Center, China
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin and immune globulin in Kawasaki disease (KD) (2 arms), sponsored by Guangzhou Women and Children's Medical Center, China. Primary endpoint: Occurrence of coronary artery abnormalities at 8 weeks from IVIG infusion. Started Jun 2023; status: recruiting.
02
Drugs
aspirinimmune globulin
03
Conditions
Kawasaki disease (KD)
Beyond the preview
Go deeper on ChiCTR2300072686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072686.